+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
PCSK9 Antagonists Market by Molecule, Application, Dosage Form, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
PCSK9 Antagonists Market by Molecule, Application, Dosage Form, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

PCSK9 Antagonists Market by Molecule, Application, Dosage Form, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6124158
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
PCSK9 antagonists have fundamentally shifted the paradigm in cardiovascular care by introducing a targeted approach to reduce low-density lipoprotein cholesterol. These biologic therapies work by inhibiting the proprotein convertase subtilisin kexin type 9 enzyme, thereby enhancing the liver’s ability to clear excess cholesterol from the bloodstream and reducing the risk of major adverse cardiovascular events.

The journey toward PCSK9 inhibition began with the recognition of genetic variants that resulted in lower cholesterol levels and diminished cardiovascular risk. This insight spurred the development of monoclonal antibodies and RNA interference agents designed to modulate PCSK9 activity. Over the past decade, this class has progressed from early research stages to widespread clinical adoption among high-risk patient populations.

Clinical trials have consistently demonstrated the efficacy and safety of PCSK9 inhibitors across diverse cohorts, including individuals with atherosclerotic cardiovascular disease and familial hypercholesterolemia. Moreover, the advent of novel molecules such as RNA-based therapies promises to extend dosing intervals and improve patient adherence, marking a significant evolution from initial monoclonal antibody platforms.

As payers, providers, and manufacturers navigate an increasingly complex healthcare environment, understanding the foundational principles of PCSK9 antagonists is essential. This introduction sets the stage for an in-depth exploration of market dynamics, regulatory developments, and strategic imperatives that will shape the future of cholesterol-lowering therapeutics.

Navigating the New Era of PCSK9 Therapeutics Driven by Breakthrough Biologics Efficacy Advances Payer Strategies and Patient Empowerment

The PCSK9 antagonist landscape is undergoing a profound transformation driven by groundbreaking advances in molecular engineering and patient-centric care models. Monoclonal antibodies and RNA interference therapies have converged to offer differentiated dosing regimens, ranging from biweekly injections to biannual administrations, thereby enhancing patient convenience and long-term adherence.

Moreover, evolving payer strategies are redefining market access through value-based contracting and outcomes-linked agreements. By aligning reimbursement with real-world clinical performance, stakeholders are incentivizing optimal utilization and ensuring that high-cost biologics deliver demonstrable improvements in patient outcomes.

Regulatory authorities have also embraced adaptive pathways, expediting review processes for therapies that address unmet medical needs. This agile framework has accelerated the approval of next-generation PCSK9 agents, enabling manufacturers to introduce innovative modalities while maintaining stringent safety and efficacy standards.

In parallel, digital health platforms and remote monitoring tools are integrating into treatment protocols to support personalized dosing schedules and track patient progress. These technological interventions foster proactive management of hypercholesterolemia and reinforce the shift toward holistic, data-driven cardiovascular care.

Assessing the Ramifications of New United States Tariff Measures on PCSK9 Antagonist Production Costs Supply Chains and Market Dynamics

Recent policy changes introducing new tariff measures have introduced additional complexity to the PCSK9 antagonist supply chain in the United States. While these duties aim to protect domestic manufacturing, they have inadvertently increased the cost of imported raw materials and active pharmaceutical ingredients critical to biologic and RNA-based production.

Consequently, manufacturers have reevaluated sourcing strategies, exploring alternative suppliers and investing in onshore facilities to mitigate exposure to cross-border levies. These adjustments have required significant capital allocation and operational realignment, challenging corporations to balance cost efficiency with uninterrupted supply.

Furthermore, the ripple effects of elevated input costs have extended to contract negotiations with payers, prompting a reassessment of pricing frameworks and reimbursement levels. Stakeholders are engaging in more nuanced dialogue to establish agreements that reflect both therapeutic value and the realities of a shifting regulatory tariff landscape.

Amid these headwinds, organizations that proactively optimize their manufacturing footprint and cultivate strategic partnerships stand to bolster resilience. By integrating tariff impact assessments into long-term planning, companies can navigate obstacles and maintain a competitive edge within the evolving regulatory environment.

Unlocking Critical Segmentation Perspectives to Illuminate How Molecule Application Formulation End User and Distribution Variables Shape the PCSK9 Landscape

Analysis based on molecule reveals that each PCSK9 antagonist targets the enzyme through distinct mechanisms, with alirocumab and evolocumab harnessing monoclonal antibody technology to neutralize circulating protein, while inclisiran utilizes RNA interference to achieve sustained enzyme reduction at the genetic level. This differential approach informs dosing intervals, manufacturing complexity, and cost considerations across the portfolio.

Application segmentation highlights the therapeutic breadth of PCSK9 antagonists, with clinical use spanning atherosclerotic cardiovascular disease alongside heterozygous and homozygous familial hypercholesterolemia. Within atherosclerotic cardiovascular disease, the focus further branches into acute coronary syndrome management, long-term stabilization of stable angina pectoris, and strategic prevention of stroke in high-risk cohorts, underscoring the versatility of these agents.

When evaluating dosage form, prefilled pens have emerged as a popular choice for patient self-administration due to ease of use and dose accuracy. Meanwhile, prefilled syringes and vials remain essential for hospital-based infusion protocols and specialty clinic administrations, offering flexibility for intravenous regimens and controlled delivery environments.

End user insights illustrate a dual adoption model, where homecare settings empower patients with self-injection capabilities, hospitals provide acute and post-acute therapeutic oversight, and specialty clinics deliver targeted education and adherence support. This multifaceted ecosystem enhances access while ensuring that clinical oversight aligns with patient needs.

Distribution channel analysis underscores the importance of diversified pathways, with hospital pharmacies facilitating inpatient and outpatient dispensing, online pharmacies catering to digital-savvy patients seeking home delivery, and retail pharmacies ensuring community-level availability. This integrated network optimizes reach and bolsters treatment continuity.

Revealing How Regional Drivers in the Americas EMEA and Asia Pacific Confer Unique Opportunities Challenges and Growth Pathways for PCSK9 Agents

In the Americas, robust clinical trial infrastructure and established healthcare reimbursement systems have fostered rapid uptake of PCSK9 antagonists among high-risk populations. Market maturity, coupled with large patient registries, enables real-world evidence generation to support value-based contracting and inform long-term safety monitoring.

Europe, the Middle East & Africa present a mosaic of regulatory pathways and reimbursement frameworks. While Western European markets have integrated PCSK9 inhibitors into national formularies through rigorous health technology assessments, emerging economies in the region are exploring tiered pricing and patient assistance programs to improve affordability and access.

Asia-Pacific markets demonstrate considerable growth potential driven by expanding cardiovascular disease prevalence and increasing healthcare infrastructure investment. Countries with established biopharmaceutical manufacturing capabilities are pursuing local production partnerships, and regional regulatory harmonization efforts are expediting the introduction of both originator and biosimilar PCSK9 therapies.

Examining Leading Industry Players Driving Innovation Competitive Dynamics Strategic Partnerships and R&D Advancements in the PCSK9 Antagonists Sector

Sanofi and its partner have leveraged an early-mover advantage by securing alirocumab approval through extensive cardiovascular outcomes trials. Their strategic focus on patient support services and co-pay assistance has reinforced product adoption in both primary and specialty care settings, establishing a robust market position.

Amgen’s evolocumab platform has been bolstered by landmark real-world evidence studies demonstrating persistent LDL-C reduction and event risk mitigation. Collaborative agreements with payers to implement outcome-based rebates have further solidified Amgen’s role as a pioneer in aligning therapeutic benefits with cost-effectiveness commitments.

Novartis’s entry with the RNA interference agent inclisiran introduced a novel dosing paradigm, offering biannual administration that reduces clinical burden and enhances adherence. Early access programs and physician education initiatives have accelerated uptake in key markets, positioning the company at the forefront of next-generation cholesterol-lowering strategies.

Emerging players and biosimilar developers are exploring niche opportunities by targeting specific patient subgroups and optimizing manufacturing processes for cost efficiencies. Strategic alliances and licensing agreements are catalyzing the expansion of pipeline candidates, promising to enrich the competitive landscape with differentiated value propositions.

Actionable Strategic Recommendations for Stakeholders to Enhance Market Positioning Optimize Patient Access and Accelerate Innovation in the PCSK9 Arena

Manufacturers should prioritize flexible production strategies that accommodate both monoclonal antibody and RNA interference platforms, ensuring supply continuity in the face of regulatory changes and tariff fluctuations. Investing in localized manufacturing capabilities and forging strategic partnerships will enhance resilience and operational agility.

Payers and healthcare systems are advised to explore outcome-based contracting models that incentivize long-term adherence and clinical efficacy. By linking reimbursement to real-world performance metrics, stakeholders can balance therapeutic value with budgetary constraints, while fostering patient access to high-impact treatments.

Healthcare providers must integrate patient education and digital monitoring tools into their care protocols to support adherence and early identification of treatment gaps. Leveraging telehealth platforms and remote lipid tracking will enable proactive intervention and strengthen the patient-clinician partnership.

Collaboration across the value chain is paramount; shared data platforms and cross-sector working groups can streamline evidence generation and accelerate regulatory alignment. By fostering a cohesive ecosystem, industry leaders can drive innovation, improve patient outcomes, and sustain market growth.

Detailing Rigorous Multimodal Research Methodology Employed to Ensure Data Integrity Comprehensive Insights and Robust Analytical Framework for PCSK9 Analysis

This research employed a multimodal methodology combining primary interviews with key opinion leaders, including cardiologists, pharmacoeconomists, and supply chain experts, to capture nuanced market perspectives and emerging clinical priorities. These qualitative insights were validated through a rigorous secondary research phase.

Secondary data collection encompassed peer-reviewed journals, regulatory filings, reimbursement submissions, and corporate disclosures to compile a comprehensive repository of clinical trial results, pricing models, and policy developments. Data triangulation techniques ensured consistency and accuracy across multiple sources.

Quantitative analyses leveraged proprietary databases to map patient demographics, treatment adoption curves, and regional healthcare spending patterns. Advanced statistical modeling underpinned scenario analyses, enabling the assessment of tariff impacts, segmentation dynamics, and competitive positioning.

All findings underwent iterative review by multidisciplinary analysts to confirm analytical integrity and relevance. The robust framework ensures that conclusions reflect the latest industry developments and provide a reliable foundation for strategic decision-making.

Synthesizing Core Takeaways and Future Outlook to Illuminate Emerging Trends Opportunities and Challenges in the Evolving PCSK9 Therapeutic Space

Throughout this executive summary, critical insights have been synthesized to illuminate how molecular innovation, payer strategies, and regional nuances converge to shape the PCSK9 antagonist market. The interplay between monoclonal antibodies and RNA interference agents underscores an enduring commitment to improved patient outcomes.

Tariff-related complexities and segmentation variances highlight the need for dynamic strategies that accommodate manufacturing nuances, diverse patient populations, and evolving regulatory frameworks. Organizations that seamlessly integrate these factors will be well positioned to capitalize on growth opportunities.

Looking ahead, the continuous emergence of real-world evidence, adaptive regulatory pathways, and digital health interventions will drive further transformation. Stakeholders that foster collaborative ecosystems, invest in advanced analytics, and maintain patient-centric models will lead the next wave of innovation in cholesterol management.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Molecule
    • Alirocumab
    • Evolocumab
    • Inclisiran
  • Application
    • Atherosclerotic Cardiovascular Disease
      • Acute Coronary Syndrome
      • Stable Angina Pectoris
      • Stroke Prevention
    • Heterozygous Familial Hypercholesterolemia
    • Homozygous Familial Hypercholesterolemia
  • Dosage Form
    • Prefilled Pen
    • Prefilled Syringe
    • Vial
  • End User
    • Homecare Settings
    • Hospitals
    • Specialty Clinics
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Amgen Inc.
  • Sanofi S.A.
  • Regeneron Pharmaceuticals, Inc.
  • Novartis AG

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing real-world adoption of inclisiran therapy driven by favorable dosing schedule and payer coverage
5.2. Strategic partnerships between biotechs and CDMOs to accelerate subcutaneous PCSK9 antibody production and diversification across geographies
5.3. Advanced pipeline strategies focusing on RNA interference and gene editing approaches targeting PCSK9 for durable lipid lowering
5.4. Competitive pricing pressures emerging from biosimilars and novel oral PCSK9 inhibitors reshaping market access dynamics
5.5. Growing emphasis on cardiovascular outcomes data integration to support PCSK9 therapy reimbursement across emerging markets
5.6. Expansion of telehealth-led lipid management programs incorporating PCSK9 antagonists to enhance patient engagement and adherence
5.7. Leveraging AI-driven predictive analytics to identify high-risk patients for PCSK9 antagonist therapy in population health management
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. PCSK9 Antagonists Market, by Molecule
8.1. Introduction
8.2. Alirocumab
8.3. Evolocumab
8.4. Inclisiran
9. PCSK9 Antagonists Market, by Application
9.1. Introduction
9.2. Atherosclerotic Cardiovascular Disease
9.2.1. Acute Coronary Syndrome
9.2.2. Stable Angina Pectoris
9.2.3. Stroke Prevention
9.3. Heterozygous Familial Hypercholesterolemia
9.4. Homozygous Familial Hypercholesterolemia
10. PCSK9 Antagonists Market, by Dosage Form
10.1. Introduction
10.2. Prefilled Pen
10.3. Prefilled Syringe
10.4. Vial
11. PCSK9 Antagonists Market, by End User
11.1. Introduction
11.2. Homecare Settings
11.3. Hospitals
11.4. Specialty Clinics
12. PCSK9 Antagonists Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas PCSK9 Antagonists Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa PCSK9 Antagonists Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific PCSK9 Antagonists Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Amgen Inc.
16.3.2. Sanofi S.A.
16.3.3. Regeneron Pharmaceuticals, Inc.
16.3.4. Novartis AG
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. PCSK9 ANTAGONISTS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. PCSK9 ANTAGONISTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. PCSK9 ANTAGONISTS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. PCSK9 ANTAGONISTS MARKET: RESEARCHAI
FIGURE 26. PCSK9 ANTAGONISTS MARKET: RESEARCHSTATISTICS
FIGURE 27. PCSK9 ANTAGONISTS MARKET: RESEARCHCONTACTS
FIGURE 28. PCSK9 ANTAGONISTS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PCSK9 ANTAGONISTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY ALIROCUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY ALIROCUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY EVOLOCUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY EVOLOCUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY INCLISIRAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY INCLISIRAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY STABLE ANGINA PECTORIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY STABLE ANGINA PECTORIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY STROKE PREVENTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY STROKE PREVENTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY PREFILLED PEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY PREFILLED PEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 85. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 86. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 87. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 88. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 89. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 90. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 91. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 92. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 93. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 98. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 99. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 100. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 101. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 102. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 103. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 104. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 105. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 110. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 122. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 148. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 154. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 160. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 161. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 162. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 163. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 164. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 165. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 166. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 167. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 172. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 173. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 174. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 175. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 176. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 177. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 178. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 179. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 184. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 189. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 190. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 191. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 196. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 197. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 198. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 199. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 200. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 201. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 202. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 203. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 208. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 209. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 210. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 211. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 212. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 213. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 214. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 215. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 232. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 238. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 244. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 250. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 256. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 257. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 258. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 259. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 260. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 261. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 262. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 263. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 268. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 271. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 272. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 273. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 274. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 275. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 280. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 281. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 282. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 283. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 284. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 285. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 286. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 287. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 290. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 291. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 292. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 293. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 294. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 295. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 296. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 297. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 298. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 299. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 300. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 301. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 302. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 303. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 304. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 305. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 306. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 307. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 308. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 309. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 310. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 311. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 312. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 313. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 314. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 315. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 316. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 317. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 318. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 319. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 320. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 321. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 322. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 323. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 324. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 325. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 326. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 327. EGYPT PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 328. EGYPT PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 329. EGYPT PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 330. EGYPT PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 331. EGYPT PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 332. EGYPT PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 333. EGYPT PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 334. EGYPT PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 335. EGYPT PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 336. EGYPT PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 337. EGYPT PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this PCSK9 Antagonists market report include:
  • Amgen Inc.
  • Sanofi S.A.
  • Regeneron Pharmaceuticals, Inc.
  • Novartis AG

Related Reports

PCSK9 Targeted Drugs Market by Company (Amgen, Novartis, Regeneron), Drug Class (Monoclonal Antibody, SiRNA), Indication, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

PCSK9 Targeted Drugs Market by Company (Amgen, Novartis, Regeneron), Drug Class (Monoclonal Antibody, SiRNA), Indication, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
PCSK9 Inhibitors (PCSK9i) disease - Epidemiology Forecast - 2032 - Product Image

PCSK9 Inhibitors (PCSK9i) disease - Epidemiology Forecast - 2032

  • Report
  • 140 Pages
  • Global
From
Cholesterol Lowering Drug Market by Drug Class (Bile Acid Sequestrants, Ezetimibe, PCSK9 Inhibitor), Route Of Administration (Injectable, Oral), Patient Age Group, Distribution Channel, Prescription Type - Global Forecast 2025-2030 - Product Image

Cholesterol Lowering Drug Market by Drug Class (Bile Acid Sequestrants, Ezetimibe, PCSK9 Inhibitor), Route Of Administration (Injectable, Oral), Patient Age Group, Distribution Channel, Prescription Type - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Hypercholesterolemia Drug Market by Drug Class, Distribution Channel, Route Of Administration, Disease Type, Age Group, Treatment Line - Global Forecast 2025-2030 - Product Image

Hypercholesterolemia Drug Market by Drug Class, Distribution Channel, Route Of Administration, Disease Type, Age Group, Treatment Line - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor - Pipeline Insight, 2025 - Product Image

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.